Molecular biology in the diagnosis of coronary heart disease;Molekylærbiologisk diagnostikk ved hjerte- og karsykdommer

Tidsskrift for den Norske Laegeforening

Volumn 118, Issue 15, 1998, Pages 2370-2374

  Berg, Kåre ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b Avdeling for Medisinsk Genetikk   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BIOLOGICAL MARKER; FIBRINOGEN; HOMOCYSTEINE; LIPID;

BLOOD; CARDIOVASCULAR DISEASE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; MOLECULAR BIOLOGY; NUCLEOTIDE SEQUENCE; REVIEW; RISK FACTOR;

ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DNA MUTATIONAL ANALYSIS; FIBRINOGEN; HOMOCYSTEINE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MOLECULAR BIOLOGY; POLYMORPHISM, GENETIC; RISK FACTORS; VARIATION (GENETICS);

EID: 0032503367     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Müller C. Angina pectoris in hereditary xanthomatosis. Arch Intern Med 1939; 64: 675-700.
2. Berg K. Genetics of coronary heart disease. I: Steinberg AG, Bearn AG, Motulsky AG, Childs B, red. Progress in medical genetics. Philadelphia: Saunders, 1983: 35-90.
3. Goldbourt U, de Faire U, Berg K, red. Genetic factors in coronary heart disease. London: Kluwer Academic Publishers, 1994.
4. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Færgeman O, Thorgeirsson G et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
5. Miller GJ, Miller NE. Plasma high-density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975; 1: 16-9.
6. Berg K, Børresen A-L, Dahlén G. Serum high density lipoprotein and atherosclerotic disease. Lancet 1976; 1: 499-504.
7. 1 -lipoprotein in patients with coronary heart disease. Clin Genet 1974; 6: 230-5.
8. Berg K. A new serum type system in man - the Lp system. Acta Path Microbiol Scand 1963; 59: 369-82.
9. Thompson GR, Wilson PW. Coronary risk factors and their assessment. London: Science Press, 1992.
10. Berg K. Lp (a) lipoprotein and disease susceptibility. I: Galteau M-M, Delwaide P, Siest G, Henry J, red. Biologic prospective. Comptes rendus du 9e Colloque de Pont-a-Mousson. Paris: John Libbey Eurotext, 1997: 223-7.
11. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
12. Heiberg A, Berg K. The inheritance of hyperlipoproteinemia with xanthomatosis. A study of 132 kindreds. Clin Genet 1976; 9: 203-33.
13. Maartmann-Moe K, Magnus P, Golden W, Berg K. Genetics of the low density lipoprotein receptor: III. Evidence for multiple normal alleles at the low density lipoprotein receptor locus. Clin Genet 1981; 20: 113-29.
14. Pedersen JC, Berg K. Normal DNA polymorphism at the low density lipoprotein receptor (LDLR) locus associated with serum cholesterol level. Clin Genet 1988; 34: 306-12.
15. Pedersen J, Berg K. Interaction between low density lipoprotein receptor (LDLR) and apolipoprotein E (apoE) alleles contributes to normal variation in lipid level. Clin Genet 1989; 35: 331-7.
16. Leren TP, Tonstad S, Gundersen KE, Bakken KS, Rødningen OK, Sundvold H et al. Molecular genetics of familial hypercholesterolemia in Norway. J Int Med 1997; 241: 185-94.
17. Rhoads GG, Dahlén G, Berg K, Morton NE, Dannenberg AL. Lp (a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986; 256: 2540-4.
18. Djurovic S, Berg K. Epidemiology of Lp(a) lipoprotein: its role in atherosclerotic/thrombotic disease. Clin Genet 1997; 52: 295-306.
19. Berg K. Confounding results of Lp(a) lipoprotein measurements with some test kits. Clin Genet 1994; 46: 57-62.
20. Boonmark NW, Lou XJ, Yang ZJ, Schwartz K, Zhang J-L, Rubin EM et al. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 1997; 100: 558-64.
21. Bohn M, Berg K. The XbaI polymorphism at the apolipoprotein B locus and risk of atherosclerotic disease. Clin Genet 1994; 46: 77-9.
22. Kondo I, Berg K, Drayna D, Lawn R. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels. Clin Genet 1989; 35: 49-56.
23. Magnus P, Berg K, Børresen A-L, Nance WE. Apparent influence of marker genotypes on variation in serum cholesterol in monozygotic twins. Clin Genet 1981; 19: 67-70.
24. Berg K. Level genes and variability genes in the etiology of hyperlipidemia and atherosclerosis. I: Berg K, Retterstøl N, Refsum S, red. From phenotype to gene in common disorders. København: Munksgaard, 1990: 77-91.
25. Berg K. Gene-environment interaction: variability gene concept. I: Goldbourt U, de Faire U, Berg K, red. Genetic factors in coronary heart disease. London: Kluwer Academic Publishers, 1994: 373-83.
26. Berg K, Malinow MR, Kierulf P, Upson B. Population variation and genetics of plasma homocyst(e)ine level. Clin Genet 1992; 41: 315-21.
27. Christensen B, Berg K. Molekylærbiologisk diagnostikk av arvelige stoffskiftesykdommer. Tidsskr Nor Lægeforen 1998; 118: 1737-42.
28. Leitersdorf E. Familial hypercholesterolaemia. I: Goldbourt U, de Faire U, Berg K, red. Genetic factors in coronary heart disease. London: Kluwer Academic Publishers, 1994: 267-73.
29. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijf P, McPherson R, Bruschke ACG et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998; 338: 86-93.